SCHEMBL6522342

SCHEMBL6522342

COc1ccc(S(=O)(=O)c2c[nH]c3ccc(Oc4c(Cl)cc([C@H](N)C(=O)O)cc4Cl)cc23)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
SMN1; SMN2 Q16637 4/20 0.46
HTT P42858 3/20 0.46
LMNA P02545 3/20 0.46
TP53 P04637 1/20 0.43
THRA P10827 1/20 0.42
THRB P10828 1/20 0.42
POLB P06746 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
PRKAB2 O43741 1/20 0.41
PRKAG1 P54619 1/20 0.41
PRKAA2 P54646 1/20 0.41
PRKAA1 Q13131 1/20 0.41
PRKAG3 Q9UGI9 1/20 0.41
PRKAG2 Q9UGJ0 1/20 0.41
PRKAB1 Q9Y478 1/20 0.41
KDM4E B2RXH2 3/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
PTGER3 P43115 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6515767 1.00 MAPT (0.53) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6520646 0.93 MAPT (0.56) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6520650 0.93 MAPT (0.56) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6512854 0.93 MAPT (0.56) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6516257 0.93 SMN1; SMN2 (0.47) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6521660 0.93 SMN1; SMN2 (0.47) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6512794 0.92 MAPT (0.43) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6512802 0.92 MAPT (0.43) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6514011 0.92 MAPT (0.43) MAPTSMN1; SMN2HTTLMNATP53
SCHEMBL6516073 0.91 SMN1; SMN2 (0.48) MAPTSMN1; SMN2HTTLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032874-A1 Anticholesterol agents; arteriosclerosis BAYER AKTIENGESELLSCHAFT (DE) 2005-02-10 US disclosed
US-6794406-B2 FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA BAYER AKTIENGESELLSCHAFT (DE) 2004-09-21 US disclosed
US-20030078288-A1 Indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078288-A1 Indole derivatives IDO1, IDO2, TPH2 MAPT 839/4885SMN1; SMN2 4749/4885HTT 399/4885
US-20050032874-A1 Anticholesterol agents; arteriosclerosis HMGCR, CYP46A1, EBP MAPT 3453/4885SMN1; SMN2 4875/4885HTT 1524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.